Investors Buy Shares of Eli Lilly and Co. (LLY) on Weakness
Traders bought shares of Eli Lilly and Co. (NYSE:LLY) on weakness during trading on Monday. $66.05 million flowed into the stock on the tick-up and $48.17 million flowed out of the stock on the tick-down, for a money net flow of $17.88 million into the stock. Of all companies tracked, Eli Lilly and had the 8th highest net in-flow for the day. Eli Lilly and traded down ($0.38) for the day and closed at $76.85
A number of analysts have recently commented on LLY shares. Leerink Swann reissued an “outperform” rating and set a $105.00 price target on shares of Eli Lilly and in a research note on Saturday, August 13th. BMO Capital Markets reissued a “buy” rating and set a $94.00 price target on shares of Eli Lilly and in a research note on Wednesday, July 27th. SunTrust Banks Inc. reissued a “buy” rating on shares of Eli Lilly and in a research note on Wednesday, June 15th. Jefferies Group reissued a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research note on Friday, May 13th. Finally, TheStreet raised Eli Lilly and from a “hold” rating to a “buy” rating in a research note on Friday, May 27th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Eli Lilly and presently has a consensus rating of “Buy” and a consensus price target of $96.58.
The firm has a market cap of $81.28 billion and a price-to-earnings ratio of 33.12. The firm has a 50-day moving average of $80.39 and a 200-day moving average of $76.26.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, hitting the consensus estimate of $0.86. The business earned $5.40 billion during the quarter, compared to analysts’ expectations of $5.14 billion. During the same quarter last year, the business posted $0.90 EPS. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. Equities analysts expect that Eli Lilly and Co. will post $3.59 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 9th. Shareholders of record on Monday, August 15th will be issued a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 2.65%. The ex-dividend date is Thursday, August 11th.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 240,000 shares of the stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $82.87, for a total value of $19,888,800.00. Following the completion of the sale, the insider now owns 126,020,570 shares in the company, valued at approximately $10,443,324,635.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jackson P. Tai acquired 2,560 shares of the company’s stock in a transaction on Friday, August 12th. The stock was acquired at an average price of $80.42 per share, with a total value of $205,875.20. Following the acquisition, the director now owns 42,110 shares in the company, valued at approximately $3,386,486.20. The disclosure for this purchase can be found here.
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.